Table 1.
Baseline characteristics of 66 subjects with PAH on inhaled prostacyclin
| Characteristic | Baseline (n = 66) |
|---|---|
| Age, mean (range), yr |
49 (18 – 74) |
| Male : Female, n (%) |
15 (23) : 51 (77) |
| White* |
58 (88) |
| PAH etiology, n (%) | |
| Idiopathic/heritable |
33 (50) |
| Collagen vascular disease |
13 (20) |
| Congenital heart disease |
17 (26) |
| HIV |
3 (5) |
| Background PAH therapy, n (%) | |
| Endothelin receptor antagonist |
56 (85) |
| Phosphodiesterase-5 inhibitor |
46 (70) |
| Both |
39 (59) |
| None |
3 (5) |
| WHO functional class, n (%) | |
| II |
38 (58) |
| III |
28 (42) |
| 6-minute walk distance, mean ± SD, m |
395 ± 79 |
| Borg dypnea score, mean ± SD |
3.4 ± 2.1 |
| Iloprost dose, n (%) | |
| 2.5 μg |
4 (6) |
| 5.0 μg |
62 (94) |
| Iloprost frequency | |
| < 6 times per day |
25 (38) |
| ≥ 6 times per day | 41 (62) |
* n = 58 (8 missing).